Adimab

Adimab is a frontrunner in human antibody discovery and engineering, boasting the creation of 450+ discovery campaigns and 55+ clinical programs with over 100 partners. The company's distinctive, yeast-based platform serves as a robust tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. It collaborates with prominent pharmaceutical and biotech companies as well as leading academic institutions. Since its establishment in 2007, Adimab has remained dedicated to pioneering protein-based therapeutic discovery to develop top-quality IgGs, multispecifics, CARs, and other modalities, aiming to ensure the success of its partners' therapeutic programs. The last known investment was a Venture - Series Unknown funding received on January 1, 2020. The identity of the investors for this round is undisclosed.